GARDN Biosciences offers an AI‑powered RNA compiler that lets researchers design and optimize RNA‑based therapeutics in seconds instead of months. The platform translates biological intent—such as protein, structural, or microRNA signals—into modular control units and assembles complete constructs with cell‑type specificity, extended duration, and reduced immunogenicity, accelerating the development of programmable RNA medicines.
Funding
Funding not disclosed
Founders
Product
Problem
Designing and optimizing RNA‑based therapeutics traditionally requires extensive laboratory cycles, large computational resources, and expert knowledge to achieve cell‑type specificity, durability, and low immunogenicity. These constraints slow development timelines and increase costs for researchers seeking novel RNA medicines.
Solution
GARDN Biosciences offers an AI‑powered RNA compiler that translates biological intent—such as protein coding, structural motifs, or microRNA signals—into fully assembled RNA constructs. The platform’s modular architecture lets users mix and match functional units (e.g., circularization motifs, tissue‑sensing elements, codon‑optimized regions) to tailor expression profiles. By leveraging data‑efficient generative models, the system provides instantaneous, interpretable design outputs without requiring datacenter‑scale compute. Researchers can iterate designs in seconds, obtaining sequences optimized for cell‑type specificity, extended duration, and reduced immunogenicity, thereby accelerating the path from concept to therapeutic candidate.
Target Audience
Primary users are biotech companies, pharmaceutical R&D teams, and academic laboratories developing mRNA, circular RNA, or other RNA‑based therapeutic modalities.
Features
- Modular design framework allowing combination of validated RNA control units (e.g., 5' UTRs, IRES, microRNA binding domains, protein recognition domains)
- AI engine that compiles biological intent into optimized RNA sequences in nanoseconds
- Data‑efficient generative models that deliver high‑performance designs without large training datasets
- Predictive analytics for cell‑type specific expression, durability, and immunogenicity reduction
- Instant, auditable design outputs enabling rapid iteration and reduced reliance on high‑end compute infrastructure